210 related articles for article (PubMed ID: 10485260)
1. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
[TBL] [Abstract][Full Text] [Related]
2. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
7. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
Cook SD; Quinless JR; Jotkowitz A; Beaton P;
Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
[TBL] [Abstract][Full Text] [Related]
8. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
9. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
[TBL] [Abstract][Full Text] [Related]
10. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.
Pungor E; Files JG; Gabe JD; Do LT; Foley WP; Gray JL; Nelson JW; Nestaas E; Taylor JL; Grossberg SE
J Interferon Cytokine Res; 1998 Dec; 18(12):1025-30. PubMed ID: 9877445
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
[TBL] [Abstract][Full Text] [Related]
12. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
[TBL] [Abstract][Full Text] [Related]
15. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
Khan OA; Xia Q; Bever CT; Johnson KP; Panitch HS; Dhib-Jalbut SS
Neurology; 1996 Jun; 46(6):1639-43. PubMed ID: 8649563
[TBL] [Abstract][Full Text] [Related]
19. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.
Wencel-Warot A; Michalak S; Warot M; Kalinowska-Lyszczarz A; Kazmierski R
Medicine (Baltimore); 2016 Nov; 95(45):e5337. PubMed ID: 27828855
[TBL] [Abstract][Full Text] [Related]
20. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
